The untapped potential of office-based buprenorphine treatment.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  JAMA psychiatry

• Publication date

  2015-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/jamapsychiatry.2014.2421PMID 25671806
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Access to treatment for opioid dependence in rural America: challenges and future directions.

  2014cited by this paper
• Medication-assisted therapies--tackling the opioid-overdose epidemic.

  2014cited by this paper
• Pharmaceutical overdose deaths, United States, 2010.

  2013cited by this paper
• Societal costs of prescription opioid abuse, dependence, and misuse in the United States.

  2011cited by this paper
• Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.

  2010cited by this paper

• Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study

  2025cites this paper
• Managing Cancer Pain in Hospitalized Patients with Comorbid Opioid Use Disorder with Buprenorphine: A Case Series

  2024cites this paper
• Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder

  2024cites this paper
• Substance Use Disorder Treatment: Opportunities for Interdisciplinary Collaboration in Neurology and Beyond

  2024cites this paper
• Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements

  2024cites this paper
• Opioid Misuse and Associated Health Risks among Adults on Probation and Parole: Prevalence and Correlates 2015–2020

  2023influential citation
• Internal and Environmental Predictors of Physician Practice Use of Screening and Medications for Opioid Use Disorders

  2023cites this paper
• Iteration is not solving the opioid crisis, it’s time for transformation

  2023cites this paper
• Physicians' experiences with buprenorphine: A qualitative study of motivations for becoming X waivered and barriers to and facilitators of prescribing the medication for opioid use disorder.

  2023cites this paper
• Statewide Trends in Buprenorphine Prescribing in Rural and Nonrural Vermont: Analysis of Population-based Patient Pharmacy Claims

  2023cites this paper
• Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care

  2023cites this paper
• Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings

  2023cites this paper
• County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.

  2022cites this paper
• Association between Prescribers’ Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability

  2022cites this paper
• Barriers to Buprenorphine Prescribing for Opioid Use Disorder in Hospice and Palliative Care.

  2022cites this paper
• Perceptions of E-cigarettes among adults in treatment for opioid use disorder

  2022cites this paper
• Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in vermont.

  2021cites this paper
• Within-subject evaluation of interim buprenorphine treatment during waitlist delays.

  2021cites this paper
• Medicaid participation among practitioners authorized to prescribe buprenorphine.

  2021cites this paper
• Unmet needs and barriers to services among people who inject drugs with HIV in the United States

  2021cites this paper
• Project Echo and Primary Care Buprenorphine Treatment for Opioid Use Disorder: Implementation and Clinical Outcomes

  2021cites this paper
• Characterizing the Clinical use of a Novel Video-assisted Dosing Protocol With Secure Medication Dispensers to Reduce Barriers to Opioid Treatment

  2021cites this paper
• Expanding Access to Medications for Opioid Use Disorder Treatment Through Incentivized Continuing Education

  2021cites this paper
• Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model

  2020cites this paper
• Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D

  2020cites this paper
• The American Opioid Epidemic in Special Populations: Five Examples.

  2020cites this paper
• Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.

  2020cites this paper
• The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.

  2020cites this paper
• Motivations for Diverted Buprenorphine Use in a Multisite Qualitative Study

  2020cites this paper
• Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

  2020cites this paper
• Clinical Pearls for Buprenorphine Treatment

  2020cites this paper
• Three-Month Outcomes from a Patient-Centered Program to Treat Opioid use Disorder

  2020cites this paper
• Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment

  2019influential citation
• Addressing Workforce Needs for Medication Treatment of Opioid Use Disorder.

  2019cites this paper
• Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study

  2019cites this paper
• Supporting Providers After Drug Overdose Death.

  2019cites this paper
• Buprenorphine in office-based opioid treatment: barriers, beliefs and benefits

  2019cites this paper
• Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder

  2019cites this paper
• Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder

  2019cites this paper
• Care and Treatment Recommendations for Pregnant Women with Opioid Use Disorder.

  2019cites this paper
• "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion.

  2019cites this paper
• Buprenorphine in the United States: Motives for abuse, misuse, and diversion.

  2019cites this paper
• Obstetrician-Gynecologists’ practice patterns related to opioid use during pregnancy and postpartum - United States, 2017

  2019cites this paper
• Stigma as a fundamental hindrance to the United States opioid overdose crisis response

  2019cites this paper
• A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States

  2019cites this paper
• Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice

  2019cites this paper
• Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder.

  2019cites this paper
• Factors Influencing Buprenorphine Prescribing among Physicians in New York State

  2019cites this paper
• Projected Contributions of Nurse Practitioners and Physicians Assistant to Buprenorphine Treatment Services for Opioid Use Disorder in Rural Areas

  2018cites this paper
• Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data

  2018cites this paper
• The Regulatory Failure to Define Essential Health Benefits

  2018cites this paper
• Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

  2018cites this paper
• Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine.

  2018cites this paper
• Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary

  2018cites this paper
• Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees

  2018cites this paper
• Use of Buprenorphine to Treat Opioid Use Disorder.

  2018cites this paper
• Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians

  2018cites this paper
• Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes

  2018cites this paper
• Telemedicine's Role in Addressing the Opioid Epidemic.

  2018cites this paper
• Why aren't physicians prescribing more buprenorphine?

  2017influential citation
• Cost‐effectiveness of emergency department‐initiated treatment for opioid dependence

  2017cites this paper
• Long-Term Buprenorphine Implants for Treatment of Opioid Dependence: Safety Outcomes from Two Open-Label Extension Trials

  2017cites this paper
• Substance use, treatment, and demographic characteristics of pregnant women entering treatment for opioid use disorder differ by United States census region.

  2017cites this paper
• Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.

  2017cites this paper
• Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact

  2017cites this paper
• Prescribing patterns of buprenorphine waivered physicians.

  2017influential citation
• From AIDS to Opioids - How to Combat an Epidemic.

  2016cites this paper
• A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.

  2016cites this paper
• Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.

  2015cites this paper
• Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

  2015cites this paper
• Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.

  2015cites this paper
• Interim treatment: Bridging delays to opioid treatment access.

  2015cites this paper
• Buprenorphine waivers: the authors reply.

  2015cites this paper